Nuvalent Inc (NUVL)

Nov 22, 2025

J.P. Morgan Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail

Nov 22, 2025

Nov 21, 2025

FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN

Nov 21, 2025

Nov 21, 2025

Four companies raise nearly $950M in follow-ons: Public Equity Report - biocentury.com

Nov 21, 2025

Nov 21, 2025

Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail

Nov 21, 2025

Nov 21, 2025

Biotech Stock Gets Booted in Latest Fund Update - AOL.com

Nov 21, 2025

Nov 21, 2025

Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com

Nov 21, 2025

Nov 21, 2025

Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com

Nov 21, 2025

Nov 20, 2025

Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights

Nov 20, 2025

Nov 20, 2025

Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria

Nov 20, 2025

Nov 20, 2025

[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan

Nov 20, 2025

Nov 20, 2025

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve

Nov 20, 2025

Nov 20, 2025

Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com

Nov 20, 2025

Nov 20, 2025

Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com

Nov 20, 2025

Nov 19, 2025

FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria

Nov 19, 2025

Nov 19, 2025

Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener

Nov 19, 2025

Nov 19, 2025

Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - MarketScreener

Nov 19, 2025

Nov 19, 2025

Nuvalent Executives Sell Over $4.6 Million in Stock - TradingView

Nov 19, 2025

Nov 19, 2025

CFO Balcom Sells 20,729 ($2.1M) Of Nuvalent Inc [NUVL] - TradingView

Nov 19, 2025

Nov 19, 2025

[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025

Nov 19, 2025

[424B5] Nuvalent, Inc. Prospectus Supplement (Debt Securities) - Stock Titan

Nov 19, 2025

Nov 19, 2025

Nuvalent announces FDA acceptance of new drug application for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC - MarketScreener

Nov 19, 2025

Nov 19, 2025

Can Nuvalent Inc. stock rebound after recent weaknessJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Nuvalent (NUVL) - The Globe and Mail

Nov 19, 2025

Nov 19, 2025

Using economic indicators to assess Nuvalent Inc. potentialStock Surge & Free Technical Confirmation Trade Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

What momentum indicators show for Nuvalent Inc. stockJuly 2025 Gainers & Safe Capital Growth Stock Tips - newser.com

Nov 19, 2025

Nov 19, 2025

Nuvalent Prices $500 Million Common Stock Offering - MarketScreener

Nov 19, 2025

Nov 19, 2025

Nuvalent prices $500 million public offering at $101 per share By Investing.com - Investing.com Nigeria

Nov 19, 2025

Nov 19, 2025

Nuvalent Announces Pricing of Public Offering of Common Stock - Finviz

Nov 19, 2025

Nov 19, 2025

Nuvalent prices $500 million public offering at $101 per share - Investing.com India

Nov 19, 2025

Nov 18, 2025

Nuvalent prices 4.95 million shares in public offering at $101.00 per share - MarketScreener

Nov 18, 2025

Nov 18, 2025

Nuvalent Prices 4.95 Million Shares In Public Offering At $101.00 Per Share - TradingView

Nov 18, 2025